ClinicalTrials.gg
CompletedNCT05045638Updated Aug 14, 2023Results posted

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

A Phase 1 interventional study of Rosuvastatin and Sotorasib in Healthy Participants, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • AMG 510
  • Sotorasib
  • Rosuvastatin
  • Healthy participants
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects or female subjects, between 18 and 60 years of age (inclusive), at the time of Screening.
  • , between 18 and 30 kg/m2 (inclusive), at the time of Screening.
  • Females of nonchildbearing potential

Exclusion criteria

Exclusion criteria:

  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • Poor peripheral venous access.
  • History or evidence, at Screening or Check in, of disorder, condition, or disease, including history of myolysis, not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Rosuvastatin alone

    Drug: Rosuvastatin

  • Experimental
    Rosuvastatin + sotorasib

    Drug: Rosuvastatin · Drug: Sotorasib

Interventions

  • DrugRosuvastatin

    Oral dose

  • Oral dose

    Also known as: AMG 510

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin

    The pharmacokinetic (PK) parameters were determined using standard non-compartmental methods.

    Time frame: Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours postdose following administration of rosuvastatin on Days 1 and 6

  2. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin

    The PK parameters were determined using standard non-compartmental methods.

    Time frame: Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours postdose following administration of rosuvastatin on Days 1 and 6

  3. AUC From Time Zero to Infinity (AUCinf) of Rosuvastatin

    The PK parameters were determined using standard non-compartmental methods.

    Time frame: Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours postdose following administration of rosuvastatin on Days 1 and 6

Secondary outcomes

  1. Number of Participants Reporting Any Treatment-Emergent Adverse Events (TEAEs)

    Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms (ECGs), and vital signs results were recorded as AEs.

    Time frame: Day 1 to Day 41

  2. Cmax of Sotorasib

    The PK parameters were determined using standard non-compartmental methods.

    Time frame: Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 6

  3. AUClast of Sotorasib

    The PK parameters were determined using standard non-compartmental methods.

    Time frame: Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 6

  4. AUCinf of Sotorasib

    The PK parameters were determined using standard non-compartmental methods.

    Time frame: Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 6

07

Results

Posted Aug 14, 2023

Participant flow

13 participants were enrolled at a single center in the United States between 20 August 2021 and 10 October 2021.

Participant flow — Overall Study
MilestoneAll Participants
Started13
Received rosuvastatin alone13
Received rosuvastatin coadministered with sotorasib13
Completed13
Not completed0

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Rosuvastatin

The pharmacokinetic (PK) parameters were determined using standard non-compartmental methods.

Time frame:
Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours postdose following administration of rosuvastatin on Days 1 and 6
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin
ng/mLRosuvastatinSotorasib + Rosuvastatin
Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin3.80 ± 57.806.47 ± 136.00
Statistical analysis
  • Rosuvastatin vs Sotorasib + Rosuvastatin · Ratio of glsms: 1.6999 · 90% CI 1.1860 to 2.4363
PrimaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin

The PK parameters were determined using standard non-compartmental methods.

Time frame:
Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours postdose following administration of rosuvastatin on Days 1 and 6
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin
h*ng/mLRosuvastatinSotorasib + Rosuvastatin
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin33.20 ± 57.0044.50 ± 73.60
Statistical analysis
  • Rosuvastatin vs Sotorasib + Rosuvastatin · Ratio of glsms: 1.3389 · 90% CI 1.0334 to 1.7347
PrimaryAUC From Time Zero to Infinity (AUCinf) of Rosuvastatin

The PK parameters were determined using standard non-compartmental methods.

Time frame:
Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours postdose following administration of rosuvastatin on Days 1 and 6
Reported as:
Geometric mean · h*ng/mL
AUC From Time Zero to Infinity (AUCinf) of Rosuvastatin
h*ng/mLRosuvastatinSotorasib + Rosuvastatin
AUC From Time Zero to Infinity (AUCinf) of Rosuvastatin36.20 ± 60.1048.40 ± 78.90
Statistical analysis
  • Rosuvastatin vs Sotorasib + Rosuvastatin · Ratio of glsms: 1.3382 · 90% CI 0.9856 to 1.8169
SecondaryNumber of Participants Reporting Any Treatment-Emergent Adverse Events (TEAEs)

Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms (ECGs), and vital signs results were recorded as AEs.

Time frame:
Day 1 to Day 41
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Treatment-Emergent Adverse Events (TEAEs)
ParticipantsRosuvastatinSotorasib + Rosuvastatin
Number of Participants Reporting Any Treatment-Emergent Adverse Events (TEAEs)00
SecondaryCmax of Sotorasib

The PK parameters were determined using standard non-compartmental methods.

Time frame:
Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 6
Reported as:
Geometric mean · ng/mL
Cmax of Sotorasib
ng/mLSotorasib + Rosuvastatin
Cmax of Sotorasib4650 ± 86.2
SecondaryAUClast of Sotorasib

The PK parameters were determined using standard non-compartmental methods.

Time frame:
Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 6
Reported as:
Geometric mean · h*ng/mL
AUClast of Sotorasib
h*ng/mLSotorasib + Rosuvastatin
AUClast of Sotorasib22500 ± 74.3
SecondaryAUCinf of Sotorasib

The PK parameters were determined using standard non-compartmental methods.

Time frame:
Predose (Hour 0), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 6
Reported as:
Geometric mean · h*ng/mL
AUCinf of Sotorasib
h*ng/mLSotorasib + Rosuvastatin
AUCinf of Sotorasib22900 ± 71.7

Adverse events

Collected over Day 1 to Day 41. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin0/13 (0%)0/13 (0%)0/13 (0%)
Sotorasib + Rosuvastatin0/13 (0%)0/13 (0%)0/13 (0%)

Baseline characteristics

The safety population included all participants who received at least 1 dose of sotorasib or rosuvastatin and had at least 1 postdose safety assessment.

Age, Continuous
Age, Continuous(years)All Participants
Mean41.5 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female2
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino10
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White9
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Covance Clinical Research Unit - Daytona Beach
    Daytona Beach, Florida 32117-5116, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Oct 2021, 1 month.

Results were first posted in Aug 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2021
First posted
Sep 16, 2021
StartActual
Aug 20, 2021
Primary completionActual
Oct 10, 2021
CompletionActual
Oct 10, 2021
Results first posted
Aug 14, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05045638
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Aug 20, 2021
Primary completion
Oct 10, 2021
Completion
Oct 10, 2021
Results posted
Aug 14, 2023
Last update
Aug 14, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion